RU2002116361A - Анальгезирующие композиции, содержащие бупренорфин - Google Patents
Анальгезирующие композиции, содержащие бупренорфинInfo
- Publication number
- RU2002116361A RU2002116361A RU2002116361/15A RU2002116361A RU2002116361A RU 2002116361 A RU2002116361 A RU 2002116361A RU 2002116361/15 A RU2002116361/15 A RU 2002116361/15A RU 2002116361 A RU2002116361 A RU 2002116361A RU 2002116361 A RU2002116361 A RU 2002116361A
- Authority
- RU
- Russia
- Prior art keywords
- buprenorphine
- naltrexone
- naloxone
- nalmefene
- range
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Claims (9)
1. Анальгезирующая композиция в парентеральной единичной дозированной лекарственной форме или в единичной дозированной лекарственной форме, пригодной для доставки через слизистую оболочку, содержащая бупренорфин в количестве меньшем, чем клиническая доза, требуемая для того, чтобы достичь успокоения боли, и
(i) налоксон в количестве таком, что массовое соотношение бупренорфина и налоксона находится в пределах от 12,5:1 до 27,5:1, или
(ii) налтрексон или налмефен в количестве таком, что массовое соотношение бупренорфина и налтрексона или налмефена находится в пределах от 12,5:1 до 22,5:1,
посредством чего анальгезирующее действие бупренорфина усиливается низкой дозой налоксона, налтрексона или налмефена.
2. Анальгезирующая композиция в парентеральной или подъязычной единичной дозированной лекарственной форме, или в единичной дозированной лекарственной форме, пригодной для доставки через слизистую оболочку, содержащей от 15 мкг до 200 мкг бупренорфина на унифицированную дозу и
(i) налоксон в количестве таком, что массовое соотношение бупренорфина и налоксона находится в пределах от 12,5:1 до 27,5:1, или
(ii) налтрексон или налмефен в количестве таком, что массовое соотношение бупренорфина и налтрексона или налмефена находится в пределах от 12,5:1 до 22,5:1.
3. Композиция по п.1 или 2, где единичная дозированная лекарственная форма содержит налоксон в количестве таком, что массовое соотношение бупренорфина и налоксона находится в пределах от 15:1 до 20:1.
4. Композиция по п.1 или 2, где лекарственная форма содержит налтрексон или налмефен в количестве таком, что массовое соотношение бупренорфина и налтрексона или налмефена находится в пределах от 15:1 до 20:1.
5. Способ лечения боли у человека или животного, включающий введение человеку или животному парентерально или через слизистую оболочку от 1,25 мкг до 10 мкг на килограмм массы тела бупренорфина в день и
(i) налоксона в количестве таком, что массовое соотношение бупренорфина и вводимого налоксона находится в пределах от 12,5:1 до 27,5:1, или
(ii) налтрексона или налмефена в количестве таком, что массовое соотношение бупренорфина и вводимого налтрексона или налмефена находится в пределах от 12,5:1 до 22,5:1.
6. Способ по п.5, в котором количество бупренорфина, вводимого человеку или животному, составляет от 1,25 мкг до 5 мкг на килограмм массы тела.
7. Способ по п.5 или 6, в котором массовое соотношение бупренорфина и налтрексона или налмефена, вводимого человеку или животному, находится в пределах от 15:1 до 20:1.
8. Применение налоксона, налтрексона или налмефена при изготовлении лекарственного средства для лечения боли, содержащего субклиническое количество бупренорфина, где массовое соотношение бупренорфина и налоксона находится в пределах от 12,5:1 до 27,5:1 или массовое соотношение бупренорфина и налтрексона или налмефена находится в пределах от 12,5:1 до 22,5:1.
9. Применение по п.8, где массовое соотношение бупренорфина и налоксона, налтрексона или налмефена находится в пределах от 15:1 до 20:1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9927359.1 | 1999-11-19 | ||
GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
US17620800P | 2000-01-14 | 2000-01-14 | |
US60/176,208 | 2000-01-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2002116361A true RU2002116361A (ru) | 2004-01-27 |
RU2255737C2 RU2255737C2 (ru) | 2005-07-10 |
Family
ID=26316086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002116361/15A RU2255737C2 (ru) | 1999-11-19 | 2000-11-17 | Анальгезирующие композиции, содержащие бупренорфин |
Country Status (31)
Country | Link |
---|---|
US (4) | US6995169B2 (ru) |
EP (1) | EP1242087B1 (ru) |
JP (1) | JP4745576B2 (ru) |
KR (1) | KR100726699B1 (ru) |
CN (1) | CN100431543C (ru) |
AR (1) | AR031682A1 (ru) |
AT (1) | ATE262335T1 (ru) |
AU (1) | AU777259B2 (ru) |
BR (1) | BR0015580A (ru) |
CA (1) | CA2392013C (ru) |
CO (1) | CO5261517A1 (ru) |
CZ (1) | CZ303160B6 (ru) |
DE (1) | DE60009346T2 (ru) |
DK (1) | DK1242087T3 (ru) |
ES (1) | ES2214334T3 (ru) |
GB (1) | GB2356348B (ru) |
HK (1) | HK1055389A1 (ru) |
HU (1) | HU229565B1 (ru) |
IL (2) | IL149580A0 (ru) |
MX (1) | MXPA02004978A (ru) |
NO (1) | NO321965B1 (ru) |
NZ (1) | NZ519023A (ru) |
PL (1) | PL199727B1 (ru) |
PT (1) | PT1242087E (ru) |
RO (1) | RO121174B1 (ru) |
RU (1) | RU2255737C2 (ru) |
SI (1) | SI21025B (ru) |
SK (1) | SK286888B6 (ru) |
TR (1) | TR200400653T4 (ru) |
TW (1) | TW550070B (ru) |
WO (1) | WO2001035942A2 (ru) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
SI2316456T1 (sl) | 2003-04-29 | 2017-10-30 | Orexigen Therapeutics, Inc. | Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion |
DK1765292T3 (en) | 2004-06-12 | 2018-01-02 | Collegium Pharmaceutical Inc | ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS |
EP2135603B1 (en) * | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
EP2089010A1 (en) | 2006-10-24 | 2009-08-19 | The John Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
KR20150082689A (ko) * | 2006-11-09 | 2015-07-15 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
GB2447014A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
PL2197429T3 (pl) | 2007-09-03 | 2016-09-30 | Kompozycje w postaci cząstek do dostarczania słabo rozpuszczalnych leków | |
US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
CA2725930A1 (en) * | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CN102724878A (zh) * | 2010-01-11 | 2012-10-10 | 奥雷西根治疗公司 | 在重度抑郁症患者中提供体重减轻疗法的方法 |
CA2991216C (en) | 2010-12-22 | 2020-04-28 | Purdue Pharma L.P. | Encased tamper resistant controlled release dosage forms |
ES2581323T3 (es) | 2010-12-23 | 2016-09-05 | Purdue Pharma Lp | Formas de dosificación oral sólida resistentes a alteraciones |
PT2706986E (pt) | 2011-09-19 | 2015-07-07 | Orexo Ab | Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos |
DK3730132T3 (da) | 2012-06-06 | 2022-08-08 | Nalpropion Pharmaceuticals Llc | Sammensætning til anvendelse ved en fremgangsmåde til behandling af overvægt og obesitas hos patienter med høj kardiovaskulær risiko |
US20150342946A1 (en) | 2013-01-30 | 2015-12-03 | Pharmorx Therapeutics, Inc. | Treatments For Depression And Other Diseases With A Low Dose Agent |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
ES2802976T3 (es) | 2013-09-10 | 2021-01-22 | Fresh Cut Dev Llc | Pulverizador de buprenorfina sublingual |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
TW201625252A (zh) | 2014-04-22 | 2016-07-16 | 大塚製藥股份有限公司 | 藥物 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
EP4100012A4 (en) * | 2020-02-05 | 2024-02-07 | Summit Biosciences Inc | MEDICINAL PRODUCTS INTENDED TO BE ADMINISTERED BY INTRANASAL ROUTE AND ASSOCIATED USES |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
AU2001259458B2 (en) * | 2000-05-05 | 2006-09-14 | Albert Einstein College Of Medicine Of Yeshiva University | Opioid antagonist compositions and dosage forms |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active IP Right Cessation
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en active IP Right Grant
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2003
- 2003-10-20 HK HK03107582.6A patent/HK1055389A1/xx not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002116361A (ru) | Анальгезирующие композиции, содержащие бупренорфин | |
JP2003514013A5 (ru) | ||
RU98111594A (ru) | Фармацевтические композиции, включающие флурбипрофен | |
ZA968808B (en) | Production of analgesic synergy by co-administration of sub-analgesic doses of a mu opioid agoinst and a kappa-2 opioid agonist | |
CA2302754A1 (en) | Noribogaine in the treatment of pain and drug addiction | |
NZ508526A (en) | Opioid formulations for treating pain | |
HK1139871A1 (en) | Improvements in and relating to medicinal compositions | |
JP2010520186A5 (ru) | ||
WO2001091736A3 (en) | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | |
NZ544645A (en) | Use of calcitonin in osteoarthritis | |
MX2009009132A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona. | |
JP2010520183A5 (ru) | ||
JP2004537500A5 (ru) | ||
RU2000132310A (ru) | Применение продуктов на основе магния для лечения или профилактики опухолевых и аутоиммунных заболеваний | |
RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
WO2005011579A3 (en) | Treatment of dependence withdrawal | |
NZ590981A (en) | Transdermal therapeutic system (TTS) for administration with a wafer | |
JP2010520184A5 (ru) | ||
MX2009009134A (es) | Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno. | |
KR20090125748A (ko) | 대상포진 후 신경통 치료용 정제 및 대상포진 후 신경통의 치료 방법 | |
WO1996030016A3 (en) | Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases | |
NZ594154A (en) | Transdermal administration of buprenorphine for preoperative treatment of post operative pain | |
CA2675760A1 (en) | Treatment of pain with naloxone | |
TW200517119A (en) | Method of treatment using interferon-tau | |
SG129278A1 (en) | A solid oral dosage form of metformin and glyburide and the method of preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20130327 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151118 |